Title:Novel Swellable/Expandable Gastroretentive Floating Films of Gliclazide Folded in Capsule Shell for the Effective Management of Diabetes Mellitus: Formulation Development, Optimization and In Vitro Evaluation
Volume: 16
Issue: 1
Author(s): Diksha Sharma and Deepak Sharma*
Affiliation:
- Department of Pharmaceutics, Rayat Bahra Institute of Pharmacy, Hoshiarpur, Punjab, 146104,India
Keywords:
Floating films, gliclazide, diabetes mellitus, gastric retention, floating time, bioavailability, controlled drug
release.
Abstract:
Background: Gliclazide (GLZ) belongs to the second-generation of sulphonylureas; it is a
drug of choice for the management of type II DM. It belongs to BCS Class II. The major site of drug
absorption for GLZ is the stomach; it displays variation in the drug absorption rate and bioavailability
due to the shorter gastric retention time. The floating mechanism gets affected when the gastric fluid
level is not sufficiently higher, which ultimately obstructs the floating behavior, which is the major
limitation of reported formulations. This limitation can be overcome by folding the film into the capsule
shell dissolved in the gastric fluid and the film swells/expands to dimensions higher than pylorus
sphincter (12mm), thus preventing its evacuation.
Objective: The study aims to explore the floating mechanism in the design of films along with a tendency
to expand by swelling and unfolding by utilizing a mixture of hydrophilic and hydrophobic polymer
to achieve the controlled drug delivery and prolonged gastric retention of drug.
Methods: The gastroretentive floating films were formulated by the solvent casting technique using 32
full factorial designs and subjected to in vitro evaluation parameters, drug-excipient compatibility, Xray
diffraction and accelerated stability study.
Results: The pre-formulation study established the purity and identification of a drug. FTIR study
confirmed no drug excipient interaction. F3, F6, and F9 were optimized based on in vitro floating
characteristics, swelling/expanding ability, and unfolding time. All developed formulations were unfolded
within 14-22 min after capsule disintegration. The F3 was selected as the final formulation as
its ability to control the release of the drug for 24 hrs followed by zero-order kinetics having super
case 2 transport. XRD confirmed the amorphousness of the drug within the formulation. The stability
study results revealed that the formulation was quite stable at extreme storage conditions.
Conclusion: The developed novel formulation has good potential for the effective management and
treatment of diabetes mellitus.
